Recently, the ISPE Facility of the Year Awards (FOYA), one of the pharmaceutical engineering industry's most prestigious award programs, announced its 2026 winners. Sanofi's Modulus biomanufacturing project was recognized with the Innovation – Facility of the Future Award and the Overall Winner.
As an important project partner, Morimatsu is honored to have contributed to this forward-looking initiative and to witness its recognition by the global pharmaceutical engineering community. This achievement underscores the Modulus project's pioneering approach to advanced manufacturing while reflecting the industry's ongoing shift toward more agile, intelligent, and sustainable production models.
From Fixed Production Lines to a Flexible Manufacturing Platform
Modulus represents a key pillar of Sanofi's biomanufacturing strategy. More than a production facility, it embodies a new manufacturing vision. Built around modular design, digital operations, and flexible manufacturing, the project comprises two highly coordinated facilities in Neuville-sur-Saône, France and Tuas, Singapore. Through standardized modules, advanced process platforms, and digital technologies, Modulus enables rapid capacity deployment and scalable expansion to meet the evolving demands of vaccine and biopharmaceutical production, setting a new benchmark for next-generation biomanufacturing facilities.
Engineering Collaboration, Turning Vision into Reality
Morimatsu's participation in the Modulus project reflects its commitment to advancing the future of biomanufacturing alongside industry partners. By providing system solutions for both the France and Singapore facilities, Morimatsu leveraged its international project execution experience, engineering standardization expertise, and global delivery capabilities to support a highly aligned system design across the two sites. While accommodating regional regulatory requirements and project-specific needs, Morimatsu contributed to the efficient delivery of the project, helping turn this vision for the factory of the future into reality.
Looking ahead to the opportunities emerging across the biomanufacturing industry, Morimatsu will continue to collaborate with global partners to explore new models of advanced manufacturing. Through professional, efficient, and integrated solutions, the company remains committed to supporting innovation and transformation in the biopharmaceutical sector and contributing its expertise and capabilities to the development of future biomanufacturing facilities worldwide.
About Sanofi
Sanofi is an R&D-driven, AI-enabled biopharmaceutical company dedicated to improving people's lives and delivering sustainable growth. Leveraging a deep understanding of the immune system, Sanofi develops innovative medicines and vaccines that help protect and improve the lives of millions of people worldwide, while its robust pipeline has the potential to benefit many more. Guided by a shared purpose, Sanofi chases the miracles of science to improve people's lives. Sanofi is driven to address some of the world's most pressing healthcare, environmental, and societal challenges. Through scientific innovation and a strong sense of responsibility, the company strives to create a positive impact for the people and communities it serves.
About ISPE FOYA
The ISPE Facility of the Year Awards (FOYA) recognizes outstanding pharmaceutical and biopharmaceutical manufacturing projects that set industry benchmarks worldwide. The 2026 award-winning projects, spanning multiple continents and therapeutic areas, collectively demonstrate the continued advancement of global pharmaceutical manufacturing in areas such as innovation, operational excellence, supply chain integration, Pharma 4.0™ implementation, and societal impact.
This year’s winners highlight significant progress in the way pharmaceutical facilities are designed, built, and operated. The awarded projects showcase a wide range of advancements, including modular and digital manufacturing approaches, sustainability-driven infrastructure development, more efficient project execution models, and enhanced integration across quality and supply systems. Collectively, these achievements underscore the critical role of engineering excellence, advanced manufacturing capabilities, and cross-functional collaboration in addressing evolving regulatory expectations, operational challenges, and societal needs. They also reflect the ongoing transformation of the global pharmaceutical manufacturing landscape toward higher quality, greater reliability, and a stronger patient-centric focus.
About Morimatsu LifeSciences
Morimatsu LifeSciences is a key business segment of Morimatsu International Holdings Limited (Stock Code: 2155.HK). It comprises Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd., Morimatsu (Suzhou) LifeSciences Co., Ltd., Shanghai Morimatsu Biotechnology Co., Ltd., Shanghai Mori-Biounion Technology Co., Ltd., Shanghai Morisora Technology Co., Ltd., Bioengineering AG, Pharmadule Morimatsu AB, and its affiliated companies.
Morimatsu LifeSciences is dedicated in providing core equipment, process systems, and smart modular facility solutions, and services for the pharmaceutical, biopharmaceutical, medical aesthetics, and fast-moving consumer goods (FMCG) sectors including (cosmetics, food, and health supplements), as well as data centers.
Our team comprises highly experienced professionals with deep expertise in process R&D, engineering design, advanced manufacturing, compliance and validation consulting, production execution, and intelligent operations. With broad experience across diverse industries, we fully understand the unique characteristics and process requirements of various products. This enables us to deliver tailored, end-to-end process solutions from the conceptual design stage, precisely aligned with client’s specific needs.
Morimatsu LifeSciences has established a strong global presence, supported by advanced R&D centers, design hubs, and state-of-the-art manufacturing facilities worldwide. Our well-established service network spans Europe,USA,Asia-Pacific, and emerging markets. We have successfully delivered outstanding, customized solutions to clients in over 40 countries and regions, gaining extensive experience in international project execution.
As a multinational enterprise with core strengths in process technology, modular facility construction, and intelligent manufacturing, Morimatsu LifeSciences is dedicated to meeting the evolving equipment and system needs of our key industries. Through continuous innovation and technological advancement, we are steadily expanding our global footprint, driving our international strategy forward, and delivering Morimatsu’s expertise, reliability, and innovation to the global life sciences and related sectors.
